Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

INTRODUCTION: In this study, we evaluated the safety and pharmacodynamic effects of the Fc-inactivated anti-β-amyloid (anti-Aβ) monoclonal antibody GSK933776 in patients with mild Alzheimer’s disease and mild cognitive impairment. Aβ and tau levels were investigated in cerebrospinal fluid (CSF), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Leyhe, Thomas, Andreasen, Niels, Simeoni, Monica, Reich, Arno, von Arnim, Christine AF, Tong, Xin, Yeo, Astrid, Khan, Shahid, Loercher, Amy, Chalker, Michelle, Hottenstein, Charles, Zetterberg, Henrik, Hilpert, Jan, Mistry, Prafull
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055052/
https://www.ncbi.nlm.nih.gov/pubmed/24716469
http://dx.doi.org/10.1186/alzrt249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055052/
https://www.ncbi.nlm.nih.gov/pubmed/24716469
http://dx.doi.org/10.1186/alzrt249

Ejemplares similares